Canbiola to Exhibit at Integrative Healthcare Symposium and Engages Hayden IR to Launch Comprehensive Investor Relations Program

Industry Tradeshow on February 21-23 at New York Hilton Midtown New York Focused on Increasing Awareness and Enhancing Shareholder Value

Hicksville, NY - (NewMediaWire) - February 20, 2019 - Canbiola, Inc. (OTCQBCANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that its executive and sales teams will be exhibiting at the Integrative Healthcare Symposium on February 21-23 in New York City. Additionally, the Company has retained Hayden IR, a national investor relations consulting firm, to implement a strategic investor relations program grounded in best practices.

The Integrative Healthcare Symposium 15th annual conference is the only event where multi-disciplinary practitioners come together as a cohesive community. Attendees gather each year to connect, learn, collaborate, and return to their practices with insights and techniques they can immediately incorporate into their patient practice. For more information, please visit https://www.ihsymposium.com. Canbiola’s executive and sales teams will be present at the tradeshow marketing the Company’s products with the ability to take orders in person.

Hayden IR will work to raise Canbiola’s visibility within the investment community by strengthening its relationships and increasing awareness with the goal of ultimately enhancing shareholder value.

“We are encouraged by our recent progress in the medical community and reception of our wide range of CBD products. The recently approved Farm Bill, which federally legalizes hemp across all 50 states provides us the macro support and fuels our optimism as we look to accelerate our roll-out of CBD offerings. We believe our recently launched Sustained Acoustic Medicine (“SAM”) wellness solution, along with its proprietary CBD Gel Capture Patches, is a game-changer for accelerating tissue healing and chronic pain reduction and will drive our revenue growth in 2019,” said Mr. Marco Alfonsi, Canbiola’s Chief Executive Officer. “As we look to all of this positive momentum, the Board and management believed it was an appropriate time to retain a proactive strategic investor relations firm to strengthen our capital markets strategy, help us reach new potential investors and effectively communicate our investment thesis. We are confident that throughout their national footprint, Hayden IR will help us more effectively communicate our accelerated growth strategy, business objectives and corporate milestones to a wider audience of sophisticated investors.”

Hayden IR (www.HaydenIR.com) is a highly regarded investor relations consulting firm known for its ability to connect underfollowed and undervalued emerging growth companies with sophisticated institutional investors, buy-side and sell-side analysts, retail brokerage firms and accredited individual investors. Leveraging decades of cumulative experience, Hayden IR develops strategies to help clients effectively communicate with the investment community and works to increase their exposure through targeted outreach and transparent positioning. Hayden IR helps public companies deliver the right message to the right audience. Over time, Hayden IR helps its clients navigate up the Wall Street value chain and to help them secure a reasonable valuation by broadening their audience, expanding institutional ownership and ensuring clear, consistent communication with the public.

About Canbiola, Inc.

Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews,, isolate, gel caps, and concentrates. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. Hemp CBD is the non-psychoactive component (No THC) used for treatment of pain, inflammation, and wellness programs.  For more information about Canbiola, Inc., please visit https://canbiola.com.

Additionally, Canbiola’s wholly owned subsidiary Pure Health Products, based in Lacey, WA, is its prime development laboratory and production facility.  Canbiola’s Duramed division has recently rolled out a durable medical device via its Doctor network to treat patients with injuries via application of an in-home SAM device.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Follow Canbiola on: 

Twitter @CanbiolaHealth

Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd
Follow us on Twitter and Facebook

Investors and Media:

IR@canbiola.com

(516) 595-9544

Hayden IR

hart@haydenir.com

(917) 658-7878
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.